Ben Haas, a partner and former Global Vice Chair of Latham’s Healthcare & Life Sciences Practice, advises clients across all stages of pre- and post-market US Food and Drug Administration (FDA) regulation and compliance.
Ben leverages extensive experience and a sophisticated understanding of FDA-regulated products to guide tobacco, medical device, pharmaceutical, biotechnology, food, cosmetic, and dietary supplement companies.
Ben is one of the most well-known and active members of the bar with respect to FDA’s ongoing efforts to implement the Tobacco Control Act and its authority over electronic nicotine delivery and other novel tobacco products, and has successfully represented several manufacturers in all types of pre-market submissions for tobacco products, including PMTAs, MRTPs, and Substantial Equivalence (SE) Reports.
A recognized thought leader, Ben has served on multiple steering committees for the Food and Drug Law Institute and regularly speaks on FDA regulatory and enforcement matters. He also recently co-authored of “Nicotine Delivery Products: Navigating FDA’s Policies in a Dynamic Environment”, a Food and Drug Law Institute publication, the key desk reference regarding FDA’s regulation of tobacco and nicotine products.
Ben counsels FDA-regulated companies on:
Firm awarded for excellence and innovation in the life science legal space.